ArticleFrontiers in pharmacology2026
Rhynchophylline attenuates porcine pseudorabies virus-induced astrocyte injury by modulating oxidative stress, inflammation, and metabolic abnormalities.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine pseudorabies virus (PRV) causes astrocyte injury through oxidative stress, inflammatory responses, and metabolic dysfunction. Rhynchophylline (RHY) possesses antioxidant and anti-inflammatory properties, but its protective effects against PRV infection remain unclear. Using PRV-infected C8-D1A cells, we evaluated the antiviral and cytoprotective effects of RHY. At a non-toxic concentration of 5 μM, RHY significantly inhibited PRV replication, reduced intracellular reactive oxygen species, and alleviated oxidative stress by decreasing xanthine oxidase (XOD), myeloperoxidase (MPO), malondialdehyde (MDA), and nitric oxide (NO) levels while restoring superoxide dismutase (SOD) activity. RHY also modulated PRV-induced inflammatory imbalance by suppressing interleukin (IL)-6 and IL-8 and enhancing IL-4 and IL-10 expression. Metabolomic profiling revealed that PRV infection disrupted cellular metabolism, particularly pathways related to unsaturated fatty acid biosynthesis and the tricarboxylic acid (TCA) cycle, which were largely restored by RHY treatment. These findings indicate that RHY exerts antiviral, anti-inflammatory, and antioxidant effects by correcting PRV-induced metabolic disturbances
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.